Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Steg

Showing results (31-40 of 1,111) with videos related to

Pageof 112
Sort By:
European Heart Journal|March 23, 2017
Duration of antiplatelet therapy after DES implantation: can we trust non-inferiority open-label trials?Philippe Gabriel Steg, Tabassome Simon
European Heart Journal|March 10, 2019
Pre-treatment with a P2Y12 antagonist before PCI in STEMI: why should we wait?Jeremie Abtan, P Gabriel Steg
Archives of Cardiovascular Diseases|June 13, 2009
Retinal microvascularisation abnormalities and cardiovascular riskLéa Mimoun, Pascale Massin, Gabriel Steg
Lancet (London, England)|March 18, 2015
Clinical evidence for oral antiplatelet therapy in acute coronary syndromesStephen D Wiviott, Philippe Gabriel Steg
European Heart Journal|November 10, 2024
Heart failure and revascularization: which method to choose and should we even do it?Nathan El Bèze, P Gabriel Steg
Journal of the American College of Cardiology|July 19, 2014
Beta-blockers in asymptomatic coronary artery disease: no benefit or no evidence?Philippe Gabriel Steg, Ranil De Silva
Circulation|February 12, 2014
Death (after percutaneous coronary intervention) is no longer what it used to bePhilippe Gabriel Steg, Adrian Piers Cheong
La Revue De Medecine Interne|April 14, 2000
[Aspirin and prevention of cardiovascular risk]D Karila-Cohen, P Gabriel Steg
Pathologie-Biologie|May 18, 2004
[Restenosis estimation at the clinical level: methodologic and angiographic aspects]J-M Juliard, P Gabriel Steg
European Heart Journal|September 24, 2019
THEMIS and THEMIS-PCIDeepak L Bhatt, Philippe Gabriel Steg
Pageof 112

Showing results (31-40 of 1,111) with videos related to

Sort By:
Pageof 112
European Heart Journal|March 23, 2017
Duration of antiplatelet therapy after DES implantation: can we trust non-inferiority open-label trials?Philippe Gabriel Steg, Tabassome Simon
European Heart Journal|March 10, 2019
Pre-treatment with a P2Y12 antagonist before PCI in STEMI: why should we wait?Jeremie Abtan, P Gabriel Steg
Archives of Cardiovascular Diseases|June 13, 2009
Retinal microvascularisation abnormalities and cardiovascular riskLéa Mimoun, Pascale Massin, Gabriel Steg
Lancet (London, England)|March 18, 2015
Clinical evidence for oral antiplatelet therapy in acute coronary syndromesStephen D Wiviott, Philippe Gabriel Steg
European Heart Journal|November 10, 2024
Heart failure and revascularization: which method to choose and should we even do it?Nathan El Bèze, P Gabriel Steg
Journal of the American College of Cardiology|July 19, 2014
Beta-blockers in asymptomatic coronary artery disease: no benefit or no evidence?Philippe Gabriel Steg, Ranil De Silva
Circulation|February 12, 2014
Death (after percutaneous coronary intervention) is no longer what it used to bePhilippe Gabriel Steg, Adrian Piers Cheong
La Revue De Medecine Interne|April 14, 2000
[Aspirin and prevention of cardiovascular risk]D Karila-Cohen, P Gabriel Steg
Pathologie-Biologie|May 18, 2004
[Restenosis estimation at the clinical level: methodologic and angiographic aspects]J-M Juliard, P Gabriel Steg
European Heart Journal|September 24, 2019
THEMIS and THEMIS-PCIDeepak L Bhatt, Philippe Gabriel Steg
Pageof 112